Updated Phase 2 Captivate Study Results Demonstrate Sustained Clinical Benefit of Fixed-Duration Imbruvica® (Ibrutinib) Plus Venetoclax as First-Line Treatment for Patients With Chronic Lymphocytic Leukaemia, Including Those With High-Risk Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.